Lower urinary tract symptoms/benign prostatic hyperplasia: Maintaining symptom control and reducing complications

Urology

Volumn 62, Issue 3 SUPPL. 1, 2003, Pages 15-23

  O'Leary, Michael P ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; FINASTERIDE; INDORAMIN; TAMSULOSIN; TERAZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; PROSTATE SPECIFIC ANTIGEN; QUINAZOLINE DERIVATIVE; STEROID 5ALPHA REDUCTASE;

CLINICAL TRIAL; DISEASE COURSE; EXPERIMENTAL MODEL; HUMAN; LIFE EXPECTANCY; NONHUMAN; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RABBIT; REVIEW; SCORING SYSTEM; TREATMENT FAILURE; TREATMENT OUTCOME; AGED; ANIMAL; DRUG ANTAGONISM; HOSPITALIZATION; MALE; TRANSURETHRAL RESECTION; URETHRA OBSTRUCTION; URINE RETENTION;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; ANIMALS; DISEASE PROGRESSION; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; QUINAZOLINES; RABBITS; SEVERITY OF ILLNESS INDEX; TESTOSTERONE 5-ALPHA-REDUCTASE; TRANSURETHRAL RESECTION OF PROSTATE; URETHRAL OBSTRUCTION; URINARY RETENTION;

EID: 0041382438     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/S0090-4295(03)00480-1     Document Type: Article

References (49)

1. Djavan B: Lower urinary tract symptoms/benign prostatic hyperplasia: fast control of the patient's quality of life. Urology 62(suppl 3A): 6-14, 2003.
2. Levin RM, Monson FC, Haugaard N, et al: Genetic and cellular characteristics of bladder outlet obstruction. Urol Clin North Am 22: 263-283, 1995.
3. Levin RM, Levin SS, Zhao Y, et al: Cellular and molecular aspects of bladder hypertrophy. Eur Urol 32(suppl 1): 15-21, 1997.
4. McNeill SA: Does acute urinary retention respond to alpha-blockers alone? Eur Urol 39(suppl 6): 7-12, 2001.
5. Michel MC, and Goepel M: Lower urinary tract symptoms suggestive of benign prostatic obstruction: what's the long-term effectiveness of medical therapies? Eur Urol 39(suppl 3): 20-25, 2001.
6. Anderson JB, Roehrborn CG, Schalken JA, et al: The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol 39: 390-399, 2001.
7. Jacobsen SJ, Jacobsen DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 158: 481-487, 1997.
8. Barry MJ, Fowler FJ, Bin L, et al: The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. J Urol 157: 10-15, 1997.
9. Wasson JH, Reda DJ, Bruskewitz RC, et al: A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med 332: 75-79, 1995.
10. Girman CJM: Population-based studies of the epidemiology of benign prostatic hyperplasia. Br J Urol 82(suppl 1): 34-43, 1998.
11. Chapple CR: Introduction and concluding remarks. Eur Urol 36(suppl 3): 1-6, 1999.
12. Schulman CC: Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment. Urology 62(suppl 3A): 24-33, 2003.
13. Djavan B, and Marberger M: A meta-analysis on the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 36: 1-13, 1999.
14. Schulman CC, Lock TMTW, Buzelin J-M, et al: Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia. J Urol 166: 1358-1363, 2001.
15. Abrams P, Schulman CC, Vaage S, et al: Tamsulosin, a selective alpha 1C-adrenoceptor antagonist: a randomised, controlled trial in patients with benign prostatic obstruction (symptomatic BPH). Br J Urol 76: 325-336, 1995.
16. Chapple CR, Wyndaele JJ, Nordling J, et al: Tamsulosin, the first prostate-selective, alpha 1A-adrenoceptor antagonist: a meta-analysis of two randomised, placebo-controlled, multi-centre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 29: 155-167, 1996.
17. Buzelin JM, Fonteyne E, Kontturi M, et al: Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 80: 597-605, 1997.
18. O'Leary M: Tamsulosin demonstrates long-term efficacy on multiple clinical and quality-of-life scoring systems. Eur Urol Suppl 1: 106, 2002. Abstract 414.
19. Lepor H, for the Tamsulosin Investigator Group: Phase II multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 51: 892-900, 1998.
20. Lepor H, for the Tamsulosin Investigator Group: Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Urology 51: 901-906, 1998.
21. Narayan P, Tewari A, for the United States 93-01 Study Group: A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. J Urol 160: 1701-1706, 1998.
22. Narayan P, and Lepor H: Long-term, open-label, phase III multicentre study of tamsulosin in benign prostatic hyperplasia. Urology 57: 466-470, 2001.
23. Elbadawi A, Diokno AC, and Millard RJ: The aging bladder: morphology and urodynamics. World J Urol 16(suppl 1): S10-S34, 1998.
24. Korstanje C, De Wijn S, Huisman A, et al: Tamsulosin and bladder hypertrophy in a rabbit model. Eur Urol Suppl 1: 61, 2002. Abstract 233.
25. Levin RM, Chichester P, Hass MA, et al: Obstructive bladder dysfunction: morphological, biochemical and molecular changes. Eur Urol Suppl 1: 14-20, 2002.
26. Levin RM, Haugaard N, O'Connor L, et al: Obstructive response of human bladder to BPH vs rabbit bladder response to partial outlet obstruction: a direct comparison. Neurourol Urodyn 19: 609-629, 2000.
27. Levin RM, Leggett RE, Eagen G, et al: Effect of doxazosin on bladder function after partial outlet obstruction in rats. J Urol 165(suppl 5): 206, 2001. Abstract 852.
28. Kojima M, Inui E, Ochiai A, et al: Reversible change of bladder hypertrophy due to benign prostatic hyperplasia after surgical relief of obstruction. J Urol 158: 89-93, 1997.
29. Kojima M, Inui E, Ochiai A, et al: Ultrasonic estimation of bladder weight as a measure of bladder hypertrophy in men with infravesical obstruction: a preliminary report. Urology 47: 942-947, 1996.
30. Sironi D, Levorato D, Deiana G, et al: The use of ultrasound estimated bladder weight (UEBW) in evaluation of change in bladder hypertrophy during treatment with an α-blocker. Eur Urol 37(suppl 2): 103, 2000. Abstract 411.
31. Sironi D, Levorato CA, Deiana G, et al: Decrease of ultrasound estimated bladder weight during tamsulosin treatment in patients with benign prostatic enlargement. Arch Ital Urol Androl 74: 90-94, 2002.
32. Coffey DS: Key messages and questions. Drugs Today 37(suppl D): 51-54, 2001.
33. Das AK, Leggett RE, Whitbeck C, et al: Effect of doxazosin on bladder function following partial outlet obstruction in rats. Neurourol Urodyn 21: 160-166, 2002.
34. Pinggera GM, Schuster A, Pallwein L, et al: Alpha-blockers increase vesical and prostatic blood flow and bladder capacity. Eur Urol Suppl 2: 159, 2003. Abstract 628.
35. Tubaro A, and Miano L: Managing the consequences of obstruction. Eur Urol Suppl 1: 21-27, 2002.
36. McConnell JD, Bruskewitz R, Walsh P, et al: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 338: 557-563, 1998.
37. Andersen JT, Nickel JC, Marshall VR, et al: Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology 49: 839-845, 1997.
38. Debruyne FMJ, Jardin A, Colloi D, et al: Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. Eur Urol 34: 169-175, 1998.
39. Kirby RS, Altwein JE, Bartsch G, et al: Results of the PREDICT (Prospective European Doxazosin and Combination Therapy) trial. J Urol 161(suppl): 266, 1999. Abstract 1027.
40. Jardin A, Bensadoun H, Delauche-Cavallier MC, et al: Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 337: 1457-1461, 1991.
41. Michel MC, Bressel H-U, Goepel M, et al: A 6-month large-scale study into the safety of tamsulosin. Br J Clin Pharmacol 51: 609-614, 2001.
42. Speakman M: Tamsulosin reduces the risk of acute urinary retention. J Urol 167(suppl 4): 375, 2002. Abstract 1492.
43. Coulange C: Tamsulosin versus tamsulosin and Serenoa repens in patients with LUTS suggestive of BPO. Eur Urol 39(suppl 5): 97, 2001. Abstract 379.
44. Clifford GM, Logie J, and Farmer RDT: How do symptoms indicative of BPH progress in real life practice? The UK experience. Eur Urol 38(suppl 1): 48-53, 2000.
45. Farmer R, Logie J, and Clifford G: The effectiveness of medical treatments in delaying the need for surgery amongst men with LUTS/BPH: a population study. BJU Int 90(suppl 2): 15, 2002. Abstract P.1.2.13.
46. McConnell JD, for the MTOPS Steering Committee: The long-term effects of medical therapy on the progression of BPH: results from the MTOPS trial. J Urol 167(suppl 4): 265, 2002. Abstract 1042.
47. De la Rosette JJMCH, Kortmann BBM, Rossi C, et al: Long-term risk of re-treatment of patients using α-blockers for lower urinary tract symptoms. J Urol 167: 1734-1739, 2002.
48. Barkin J, Guimaraes M, Jacobi G, et al: Dutasteride provides sustained symptom relief following short-term combination treatment with tamsulosin. J Urol 167(suppl 4): 372, 2002. Abstract 1481.
49. Diamond SM, Ismail M, Hubosky S, et al: Placebo-controlled trial of alpha blockade and finasteride in men with enlarged prostates and LUTS: subjective and objective results after discontinuation of alpha blockade. J Urol 167(suppl 4): 373, 2002. Abstract 1484.